Company intelligence / Profile preview

NuPathe Inc.

Malvern, Pennsylvania, United Statestevapharm.com ↗

Ownership: Private
Employees: ~22
Development stage: Commercial

Overview

NuPathe developed ZECUITY, the first and only FDA-approved prescription migraine patch for acute treatment of migraine with or without aura in adults. ZECUITY was approved based on phase 3 trials that included 793 patients using nearly 10,000 ZECUITY patches. The trials demonstrated a favorable safety profile and effectiveness at relieving migraine headache pain and migraine-related nausea two hours after patch activation.[1]

Therapeutic areas: PsychiatryNeurology
Modalities: Transdermal patch delivery system
Industry: Biotech

Drug pipeline

1 asset

sumatriptan

Commercial

Indications: Migraine, Migraine with aura

Beyond the preview

Go deeper on NuPathe Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuPathe Inc..

Explore the full profile